Document is current
Any future updates will be listed below
-
Authors
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Dooley, Katharine https://orcid.org/0000-0003-4565-5767
Geyer, Susan https://orcid.org/0009-0002-5649-6909
Gerstner, Elizabeth R.
Kaufmann, Timothy J.
Iafrate, A. John
Martinez-Lage, Maria https://orcid.org/0000-0002-5859-7562
Milhem, Mohammed
Welch, Mary Roberta
Kaley, Thomas J.
Drappatz, Jan
Chan, Amy
Kumthekar, Priya https://orcid.org/0000-0001-5923-0677
Matsuoka, Carlos Kamiya https://orcid.org/0000-0003-3216-2728
Strowd, Roy E.
Cohen, Adam L.
Jaeckle, Kurt https://orcid.org/0000-0002-7827-463X
Robell, Lindsay
Magge, Rajiv S.
Nam, Joo Yeon https://orcid.org/0000-0001-9071-0484
Blondin, Nicholas
Shaikh, Nawal
Rabinowitz, Ian https://orcid.org/0000-0003-3377-4865
Thomas, Alissa A.
Piccioni, David E.
Brown, Paul
Kaluziak, Stefan
Codd, Elizabeth
Cahill, Daniel P.
Santagata, Sandro
Barker, Frederick G. II
Galanis, Evanthia https://orcid.org/0000-0001-8014-786X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Eli Lilly and Company
GlaxoSmithKline
Damon Runyon Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 10 February 2025
Accepted: 21 November 2025
First Online: 16 January 2026
Competing interests
: A.J.I. receives royalties from Invitae and is a consultant for AstraZeneca, Repare Therapeutics, PAIGE.AI, SequreDx and Intellia. A.L.C. has institutional grants and contracts from Chimerix, BPGbio, Nuvox, the University of Utah and Novocure. A.T. serves as site principal investigator for two industry-supported studies with Novocure and ONO Pharmaceuticals. D.P.C. has received financial compensation from Servier (2023), Boston Scientific (2025), Incephalo (2023), Pyramid Biosciences (equity options 2021), Lilly (2020), GlaxoSmithKline (2021) and Boston Pharmaceuticals (2020) for advisory input. He has also received financial compensation and travel reimbursement from Merck for invited lectures (2016), and from the US National Institutes of Health and Department of Defense for clinical trial and grant review (2025). E.G. serves on the advisory board for Kiyatec (personal compensation), Karyopharm Therapeutics, Boston Scientific, Servier Pharmaceuticals, Boehringer Ingelheim and Modifi Biosciences (compensation to employer), and has received grant, research and clinical trial funding (to Mayo) from Servier Pharmaceuticals and Denovo Biopharma. P.K. has received grants from Genentech and Novocure, consulted for Belay Diagnostics, FYR Diagnostics, Plus Therapeutics, Enclear Therapeutics, Affinia Therapeutics, Biocept, Janssen, Bioclinical, Mirati, Novocure, Servier, Telix Pharmaceuticals and Biodexa, received payments and honoraria from Seagen, and participated in data safety monitoring board or advisory board for BPGBio and In8Bio. P.K.B. has consulted for Voyager Therapeutics, Tesaro, SK Life Science, Sintetica, Pfizer, Merck, ElevateBio, Dantari, Angiochem, MPM, Medscape, Kazia, InCephalo, Genentech, Eli Lilly, CraniUS, Axiom, Atavistik and Advise Connect Inspire, serves on the scientific advisory board for Kazia, Selectin Therapeutics (with equity) and CraniUS, and has received speaker’s honoraria from the International Academy for Advanced Oncology, Genentech and Pfizer. She has received institutional research support (to MGH) from Kinnate, Mirati, Merck and Eli Lilly. The other authors declare no competing interests.
